Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Patients | Zendy

Alexander T Cohen | Zendy; Theodore E. Spiro | Zendy; Harry R. Büller | Zendy; Lloyd Haskell | Zendy; Dayi Hu | Zendy; Russell D. Hull | Zendy; Alexandre Mebazaa | Zendy; Geno J. Merli | Zendy; Sebastian Schellong | Zendy; Alex C. Spyropoulos | Zendy; Victor F. Tapson | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Patients

Author(s) -

Alexander T Cohen,

Theodore E. Spiro,

Harry R. Büller,

Lloyd Haskell,

Dayi Hu,

Russell D. Hull,

Alexandre Mebazaa,

Geno J. Merli,

Sebastian Schellong,

Alex C. Spyropoulos,

Victor F. Tapson

Publication year - 2013

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1111096

Subject(s) - medicine , rivaroxaban , placebo , clinical trial , anesthesia , emergency medicine , surgery , warfarin , atrial fibrillation , alternative medicine , pathology

The clinically appropriate duration of thromboprophylaxis in hospitalized patients with acute medical illnesses is unknown. In this multicenter, randomized, double-blind trial, we evaluated the efficacy and safety of oral rivaroxaban administered for an extended period, as compared with subcutaneous enoxaparin administered for a standard period, followed by placebo.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research